Palliative care integration and end-of-life care intensity for patients with NSCLC
-
Published:2024-06
Issue:
Volume:192
Page:107800
-
ISSN:0169-5002
-
Container-title:Lung Cancer
-
language:en
-
Short-container-title:Lung Cancer
Author:
Martin A.,
Carton M.ORCID,
Thery L.ORCID,
Burnod A.,
Daniel C.ORCID,
Du Rusquec P.,
Girard N.,
Bouleuc C.ORCID
Reference39 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin.,2021
2. Lung Cancer Staging and Prognosis;Woodard;Cancer Treat Res.,2016
3. Prognostic influence of PD-1/PD-L1 suppressors in combination with chemotherapeutic agents for non-small cell pulmonary carcinoma: system review and meta-analysis;Shen;Front Oncol.,2023
4. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer;Gadgeel;J Clin Oncol.,2020
5. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet.,2019